Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Ovarian Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Non Small Cell Lung Carcinoma NSCLC 2Neoplasm Metastasis 2Melanoma 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Triple Negative Metastatic Breast Cancer 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Peritoneal Neoplasms 1Non-Small Cell Lung Cancer With HER2- Mutations 1Neoplasms, Unknown Primary 1Neoplasms 1NSCLC 1Head and Neck Neoplasms 1First-line Advanced NSCLC Patients 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Ovarian Epithelial 1Carcinoma 1

Interventions

Carboplatin 7aflutinib 5Pemetrexed 5osimertinib 4Gefitinib 4HM781-36B 3rezivertinib 2pembrolizumab 2Paclitaxel 2HMPL-013 2Docetaxel 2Cisplatin 2Albumin-Bound Paclitaxel 2tipifarnib 1sulindac sulfone 1spartalizumab 1icotinib 1aumolertinib 1apatinib 1Vinorelbine 1Taxes 1Gemcitabine 1Erlotinib Hydrochloride 1Clinical Trials, Phase I as Topic 1Cetuximab 1CP protocol 1Bortezomib 1BID protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × NSCLC × CP protocol × Clear all
NCT00576225 2020-10-19

CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL

CTI BioPharma

Phase 3 Withdrawn
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡